Apitraz 500 mg Bee-hive Strips for Honey Bees

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: VMD (Veterinary Medicines Directorate)

Nunua Sasa

Tabia za bidhaa Tabia za bidhaa (SPC)
12-04-2022

Viambatanisho vya kazi:

Amitraz

Inapatikana kutoka:

Laboratorios Calier, SA

ATC kanuni:

QP53AD01

INN (Jina la Kimataifa):

Amitraz

Dawa fomu:

Bee-hive strip

Dawa ya aina:

AVM-GSL - Authorised Veterinary Medicine – General Sales List

Kundi la matibabu:

Honey bees

Eneo la matibabu:

Ectoparasiticide

Idhini hali ya:

Authorized

Idhini ya tarehe:

2016-04-26

Tabia za bidhaa

                                Revised: April 2022
AN: 02248/2021 & 02250/2021
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Apitraz 500 mg bee-hive strips for honey bees
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 27.6 g strip contains:
ACTIVE SUBSTANCE:
Amitraz...................................500 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Bee-hive strip
White rectangular plastic strip with two tabs and a marker fold line.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Honey bees – _Apis mellifera_
4.2
INDICATIONS FOR USE,SPECIFYING THE TARGET SPECIES
Treatment of external parasitosis in honey bees caused by _Varroa
destructor _
sensitive to amitraz.
4.3
CONTRAINDICATIONS
Do not use in the case of known resistance to amitraz.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
All colonies in the same apiary should be treated simultaneously to
avoid robbery.
Do not re-use the strips_. _
It is recommended not to use the product before the end of the honey
producing season
of the year. See also section 4.9: Precautions of use and application
timetable.
Inappropriate use of the product could result in an increased risk of
resistance
development and could ultimately result in ineffective therapy.
Bee colonies should be monitored routinely for the level of varroa
mite infestation
during treatment and also for a period thereafter.
The product should be used as part of an integrated varroa control
programme.
Revised: April 2022
AN: 02248/2021 & 02250/2021
Page 2 of 5
Amitraz resistance has been reported in some populations of Varroa
mites.
In countries with recognized amitraz resistance or in case of
suspicion of amitraz
resistance, the use of the product should ideally be based on results
of susceptibility
testing (e.g. Beltsville test). Please speak to your veterinarian or
local bee inspector
for further information.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
The safety profile for the product has not been established in weak
colonies, i.e. thos
                                
                                Soma hati kamili
                                
                            

Tafuta arifu zinazohusiana na bidhaa hii